The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP)

Dupilumab and other biologics have revolutionized the management of recalcitrant polyps in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Despite strong evidence for the efficacy of dupilu...

Source: Journal of Otolaryngology - Head and Neck Surgery - September 28, 2023 Category: ENT & OMF Authors: Scott A. Hardison and Brent A. Senior Tags: Commentary Source Type: research